Absci Corp (ABSI) Stock Price & Analysis
Absci Corp (ABSI) fell 6.32% to USD 7.56 as of July 25, 2026 at 15:45 UTC, according to Nexqual real-time market data.
ABSI last closed at USD 8.07; the session ranged USD 7.51–8.26 on volume of 2,523,790 shares. Market capitalization is $1.28B, with a 52-week range of USD 2.24–12.06 (NMS). Source: Nexqual, July 25, 2026 at 15:45 UTC.
Key Statistics (as of July 25, 2026 at 15:45 UTC)
| Price | USD 7.56 |
|---|---|
| Change | ▼ 6.32% (down) |
| Previous Close | USD 8.07 |
| Open | USD 8.13 |
| Day Range | USD 7.51 – 8.26 |
| 52-Week Range | USD 2.24 – 12.06 |
| Volume | 2,523,790 shares |
| Market Cap | $1.28B |
| Exchange | NMS |
Technical Analysis (ABSI)
Nexqual's technical model rates ABSI "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 15:45 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 38.96 (neutral) |
| vs SMA50 | Below (USD 7.88) |
| MACD | -0.1 (negative) |
Analyst Ratings (ABSI)
Wall Street analysts rate ABSI "Strong Buy" based on 9 analysts, with a mean price target of USD 13.78 (range USD 10–17), per Nexqual as of July 25, 2026 at 15:45 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 13.78 |
| High Target | USD 17 |
| Low Target | USD 10 |
| Buy / Hold / Sell | 9 / 1 / 0 |
Earnings (ABSI)
| Next Earnings Date | 2026-08-11 |
|---|---|
| EPS Estimate | USD -0.2 |
| Revenue Estimate | $931,670 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.19 vs est -0.2 ▲ beat |
| 2025-12-31 | USD -0.23 vs est -0.17 ▼ miss |
| 2025-09-30 | USD -0.2 vs est -0.21 ▲ beat |
| 2025-06-30 | USD -0.24 vs est -0.21 ▼ miss |
Source: Nexqual, July 25, 2026 at 15:45 UTC.
Financials & Fundamentals (ABSI)
| Total Revenue | $1.84M |
|---|---|
| Revenue Growth (YoY) | -81.80% |
| Gross Margin | +0.00% |
| Operating Margin | -14346.98% |
| Profit Margin | +0.00% |
| ROE | -63.89% |
| Debt / Equity | 2.57 |
| Current Ratio | 6.59 |
| Total Cash | $125.70M |
| Total Debt | $4.42M |
| Free Cash Flow | $-41.48M |
Source: Nexqual, July 25, 2026 at 15:45 UTC.
Financial Health Score (ABSI)
Nexqual rates Absci Corp's overall financial health "Weak" across five dimensions, as of July 25, 2026 at 15:45 UTC.
| Growth | Critical — Revenue -38% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $126M cash vs $4M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$41M, burning cash |
| Efficiency | Critical — ROE -64%, ROA -37.3% |
Ownership (ABSI)
| Insider Ownership | +12.04% |
|---|---|
| Institutional Ownership | +73.07% |
| Shares Outstanding | 169.40M |
| Float | 148.72M |
| Short % of Float | +25.75% |
Source: Nexqual, July 25, 2026 at 15:45 UTC.
Leadership (ABSI)
Absci Corp is led by Sean McClain (age 35), Founder, CEO, President & Director, per Nexqual as of July 25, 2026 at 15:45 UTC.
| Founder, CEO, President & Director | Sean McClain (age 35) |
|---|---|
| Chief Business Officer & CFO | Zachariah Jonasson (age 52) |
| Senior Vice President of People & Experience | Jeanne Schreuder M.B.A., SPHR |
| Senior Vice President of Portfolio & Growth Strategy | Christine Lemke D.V.M. |
| Vice President of Research | Amer-Denis Akkad |
Major Backers & Investors (ABSI)
Notable institutional backers of Absci Corp include ARK Invest, FMR, LLC, Fidelity, according to Nexqual as of July 25, 2026 at 15:45 UTC.
Active Investors
| Investor | Stake |
|---|---|
| ARK Invest | 17.29% |
| FMR, LLC | 14.46% |
| Fidelity | 8.33% |
| Redmile Group, LLC | 5.29% |
| Advanced Micro Devices Inc | 3.67% |
| Woodline Partners LP | 2.12% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.32% |
| State Street | 8% |
| Vanguard Group | 6.51% |
| Geode Capital | 2.14% |
Source: Nexqual, July 25, 2026 at 15:45 UTC.
From Absci Corp's Latest SEC 10-K Filing (filed 2026-03-24)
Key Strengths & Strategy (as disclosed to the SEC)
- Advancing AI drug creation by leveraging our proprietary data: We use data generated through our programs and design campaigns to support the continued development of our AI models.
- Intellectual Property We strive to protect and enhance the proprietary technology, inventions, know-how and improvements that we believe are commercially important to our business by seeking, maintaining, and defending patent rights, whether developed internally or licensed from third parties, that cover our Integrated Drug Creation platform, as well as our internally developed programs.
- Biologics License Application (BLA) Submission and Review Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, preclinical studies and clinical trials are submitted to the FDA as part of a B
- Our Integrated Drug Creation Platform Absci is a clinical-stage, AI-native biopharmaceutical company.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RXRX | Recursion Pharmaceuticals, Inc. | USD 2.96 | ▼ 0.67% |
| PRME | Prime Medicine, Inc. | USD 2.95 | ▼ 4.53% |
| ABOS | Acumen Pharmaceuticals, Inc. | USD 2.13 | ▼ 3.62% |
| SANA | Sana Biotechnology, Inc. | USD 3.18 | ▲ 1.92% |
| RLAY | Relay Therapeutics, Inc. | USD 18.44 | ▼ 4.31% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 15:45 UTC. This page is informational and not investment advice.